GIP and obesity due to melanocortin 4 receptor deficiency: Our data show that this newly developed in vitro model of pancreatic adipose tissue can serve as robust tool for investigating (patho)physiological traits of this adipose tissue depot, including the effects of GLP-1, GIP, and dual GLP-1/GIP receptor agonists, which currently are the best in class pharmacological agents to treat T2D and obesity.